Homology Medicines Inc FIXX:NASDAQ

Last Price$1.97NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22

Today's Change0.00(0.00%)
Bid (Size)$1.97 (5)
Ask (Size)$2.01 (5)
Day Low / High$1.86 - 2.02
Volume124.8 K

View Biotechnology IndustryPeer Comparison as of 06/30/2022


Homology Medicines Inc ( NASDAQ )

Price: $1.97
Change: 0.00 (0.00%)
Volume: 124.8 K
4:00PM ET 6/30/2022

ContraFect Corp ( NASDAQ )

Price: $3.07
Change: +0.17 (5.86%)
Volume: 111.5 K
4:00PM ET 6/30/2022

Adverum Biotechnologies Inc ( NASDAQ )

Price: $1.20
Change: +0.02 (1.69%)
Volume: 829.0 K
4:00PM ET 6/30/2022

Champions Oncology Inc ( NASDAQ )

Price: $8.00
Change: +0.15 (1.91%)
Volume: 5.2 K
3:56PM ET 6/30/2022

Leap Therapeutics Inc ( NASDAQ )

Price: $1.15
Change: -0.04 (3.36%)
Volume: 328.5 K
4:00PM ET 6/30/2022

Read more news Recent News

Homology Medicines Says Clinical Hold Lifted on Trial of Investigational Gene Therapy for Blood Disorder; Shares Gain Pre-Bell
9:01AM ET 6/13/2022 MT Newswires

Homology Medicines (FIXX) said Monday that the US Food and Drug Administration has lifted a clinical hold on a trial of the company's HMI-102...

Chardan Trims Homology Medicines' Price Target to $14 From $15, Reiterates Buy Rating
4:48AM ET 5/17/2022 MT Newswires

Homology Medicines (FIXX) has an average rating of outperform and price targets ranging from $4 to $29, according to analysts polled by Capital IQ. (MT...

--Credit Suisse Initiates Homology Medicines at Neutral, $2.70 Price Target
11:07AM ET 4/28/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Canaccord Genuity Adjusts Homology Medicines' Price Target to $7 From $19, Maintains Buy Rating
9:26AM ET 4/06/2022 MT Newswires

Homology Medicines (FIXX) has an average rating of outperform and price targets ranging from $4 to $29, according to analysts polled by Capital IQ. (MT...

Company Profile

Business DescriptionHomology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the design and development of treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing, and gene therapy technologies into novel treatments for patients with rare diseases. The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA. View company web site for more details
AddressOne Patriots Park
Bedford, Massachusetts 01730
Number of Employees124
Recent SEC Filing06/17/20224
Chief Executive Officer & DirectorArthur O. Tzianabos
President & Chief Scientific OfficerAlbert Seymour
Senior VP, Head-Clinical Development & OperationsJulie Jordan
Treasurer, Chief Financial & Business OfficerW. Bradford Smith

Company Highlights

Price Open$1.91
Previous Close$1.97
52 Week Range$1.30 - 8.90
Market Capitalization$113.0 M
Shares Outstanding57.4 M
SectorHealth Technology
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.07
Beta vs. S&P 500N/A
Revenue$3.7 M
Net Profit Margin-47.29%
Return on Equity-1.20%

Analyst Ratings as of 05/12/2022

Consensus RecommendationConsensus Icon
Powered by Factset